Fei Chen | Synthetic Biology | Cost-effectiveness Award Published on 21/11/202421/11/2024 by ScienceFather Fei Chen | Synthetic Biology | Cost-effectiveness Award Dr. Fei Chen, Beijing Institute of Genomics, China. Dr. Fei Chen is a distinguished Professor at the Beijing Institute of Genomics, Chinese Academy of Sciences (CAS), and the University of Chinese Academy of Sciences. As Chief Scientist for the National Key R&D Program, Dr. Chen specializes in pathogenic microorganism genomics, infectious disease genomics, synthetic biology, and biosecurity. With over 60 publications in leading journals like PNAS and JACS, he holds 20+ patents. Recruited through CAS’s “Hundred Talents Program,” he has led over 30 research projects with funding exceeding 30 million RMB. His achievements are recognized by prestigious awards, including the Chinese Medical Science and Technology Award. Publication profile Scopus Googlescholar Education Ph.D. in Biology (Institution: CAS) Postdoctoral Researcher in Genomics Experience Professor (PI) at Beijing Institute of Genomics, CAS Chief Scientist, National Key R&D Program Editorial Board Member of multiple international journals Principal Investigator for over 30 funded research projects Suitability For The Award Dr. Fei Chen is an outstanding candidate for the Cost-Effectiveness Award due to his ability to maximize scientific impact and innovation while efficiently utilizing resources. His exemplary track record of high-impact research in genomics, biosecurity, and synthetic biology demonstrates strategic allocation of funding and significant contributions to addressing critical global health challenges. Dr. Chen’s leadership in research projects, prolific publication record, and innovative patents showcase his commitment to advancing science with optimal resource management. Professional Development Dr. Fei Chen’s career reflects an unwavering commitment to advancing scientific research in genomics, biosecurity, and synthetic biology. Recruited through the prestigious CAS “Hundred Talents Program” (Category A), he has rapidly risen as a leading figure in his field. With more than 60 publications, numerous patents, and an impressive portfolio of national and international projects, Dr. Chen continuously pushes the boundaries of scientific discovery. His leadership is reflected in his role as Chief Scientist and his contributions to bioinformatics, with a focus on infectious diseases and biosecurity innovations. His academic roles keep him at the forefront of his field. Research Focus Dr. Fei Chen’s research primarily focuses on pathogenic microorganism genomics, infectious disease genomics, synthetic biology, and biosecurity. His pioneering work aims to understand the molecular mechanisms behind infectious diseases and develop novel synthetic biological approaches for improving biosecurity and disease prevention. By integrating cutting-edge genomic techniques, his research is crucial in combating global health challenges and advancing the field of bioinformatics. His work also bridges the gap between academic research and real-world applications, particularly in controlling infectious diseases and enhancing public health systems worldwide. Awards and Honors Chinese Medical Science and Technology Award Huaxia Medical Science and Technology Award CAS “Hundred Talents Program” (Category A) Recruitment National Key R&D Program Chief Scientist Over 20 authorized patents, including 4 PCT patents Publications Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024 – Nucleic Acids Research, 2024, 52(1 D), cited by 50 HervD Atlas: A curated knowledgebase of associations between human endogenous retroviruses and diseases – Nucleic Acids Research, 2024, 52(D1), cited by 5 Spatiotemporal single-cell transcriptomic profiling reveals inflammatory cell states in a mouse model of diffuse alveolar damage – Exploration, 2023, 3(3), cited by 11 Comparative transcriptome analysis of SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E identifying potential IFN/ISGs targets for inhibiting virus replication – Frontiers in Medicine, 2023, 10, cited by 0 Genomic epidemiology and heterogeneity of Providencia and their bla NDM-1-carrying plasmids – Emerging Microbes and Infections, 2023, 12(2), cited by 4 Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism – Frontiers in Cellular and Infection Microbiology, 2023, 13, cited by 0 Comparative genomic analysis reveals differential genomic characteristics and featured genes between rapid- and slow-growing non-tuberculous mycobacteria – Frontiers in Microbiology, 2023, 14, cited by 0